SCHEMBL5014453

SCHEMBL5014453

CC(N)(O)C(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4172762 0.82
SCHEMBL3719577 0.77
SCHEMBL6276402 0.75
SCHEMBL31316344 0.75
SCHEMBL7600038 0.73
SCHEMBL17006478 0.73
SCHEMBL6889246 0.73
SCHEMBL6190368 0.73
SCHEMBL134266 0.73
SCHEMBL16817799 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670446-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2006-06-21 EP claimed
WO-2005030185-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2005-04-07 WO claimed
CN-109715637-B Glucokinase activators and methods of use thereof 百时美施贵宝公司 2022-04-05 CN disclosed
EP-3464248-B1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES Bayer Pharma AG (DE) 2021-09-08 EP disclosed
US-11040035-B2 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-06-22 US disclosed
US-20200237757-A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-07-30 US disclosed
CN-109863140-A 3- oxo -2,6- diphenyl -2,3- dihydrogen dazin -4- formamide 拜耳医药股份有限公司 2019-06-07 CN disclosed
EP-3464248-A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES Bayer Pharma Aktiengesellschaft (DE) 2019-04-10 EP disclosed
EP-3303294-A1 SUBSTITUTED PYRIDINES AND METHOD OF USE Abbvie S.a.r.l. (LU) 2018-04-11 EP disclosed
WO-2017202816-A1 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-30 WO disclosed
WO-2016193812-A1 SUBSTITUTED PYRIDINES AND METHOD OF USE ABBVIE S.A.R.L. (LU) 2016-12-08 WO disclosed
WO-2007070173-A2 CETP INHIBITORS MERCK & CO., INC. (US) 2007-06-21 WO disclosed
EP-1670446-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2006-06-21 EP disclosed
WO-2005030185-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2005-04-07 WO disclosed
EP-1115695-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP disclosed
EP-1115693-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP disclosed
WO-2000018724-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO disclosed
WO-2000018721-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO disclosed
CN-1034497-C Process for the preparation of aromatic aminoalcohol derivatives useful for the treatment of diabetes and obesity SANKYO CO (JP) 1997-04-09 CN disclosed
CN-1073428-A Aromatic amino alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic use SANKYO CO (JP) 1993-06-23 CN disclosed